Viatris is beginning to deliver on at least one of its complex generic injectables – long-promised by the US company as part of a deep and differentiated pipeline – as it pledged to provide further details at the firm’s upcoming company investor day.
Viatris says its US generic glucagon 1mg/vial injectable is “actively being launched,” as the firm looks to deliver on its long-promised string of complex injectables going into a challenging 2025.
News of the launch came as Viatris revealed that the US Food and Drug Administration warning letter and import alert...
The first new drug for fibromyalgia since 2009, Tonmya is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.
Glenmark expects to restart US commercial production at its Monroe, North Carolina injectables plant soon, after a recent FDA inspection resulted in a Form 483 with five procedural GMP observations, but none related to data integrity.
Rumours are circulating that Aurobindo could be set to take ownership of Zentiva from current owner Advent in a $5bn transaction, which would represent one of the largest off-patent sector deals in some time.
As Alvotech announced first-half results that outpaced expectations, the biosimilars developer’s management explained that the firm was targeting value and product margin over market share and volumes.
Fresenius Kabi’s IV drugs and fluids Pharma division rebounded in Q2, led by strong US and European volumes, especially in infusion therapies. Biopharma revenue rose by 26% to €190m, up one-third in constant currencies, driven by tocilizumab biosimilar ramp-up in Europe and the US.
Gedeon Richter’s management discussed timelines for two key biosimilars during the firm’s first-half earnings call, while also revealing how the firm’s General Medicines division had suffered setbacks in the three months to June 30.
Viatris is conducting a company-wide strategic review to boost long-term competitiveness, targeting cost savings and a shift to complex, high-margin products. CEO Scott Smith says it’s timely after four divestitures. An update is due in the Q3 2025 earnings call in November.
